A Demonstration Project to Add Pre- or Post-exposure Prophylaxis to Combination HIV Prevention Services
| Status: | Completed |
|---|---|
| Conditions: | HIV / AIDS |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/17/2018 |
| Start Date: | May 2013 |
| End Date: | May 2016 |
A Pilot Demonstration Project to Operationalize Pre-exposure Prophylaxis as Part of Combination HIV Prevention Among Men Who Have Sex With Men (MSM) and Transgender Women in Los Angeles County
The purpose of this study is to evaluate the safety, acceptability and feasibility of
delivery of Pre-Exposure Prophylaxis (PrEP) or Post-Exposure Prophylaxis) PEP as part of
combination HIV prevention services for high-risk MSM and transgender women.
delivery of Pre-Exposure Prophylaxis (PrEP) or Post-Exposure Prophylaxis) PEP as part of
combination HIV prevention services for high-risk MSM and transgender women.
Two community-based sites (LALGBT Center and The OASIS Clinic) will serve as facilities at
which participants may present for screening for prevention services. At the sites,
eligibility criteria will be assessed, HIV, Sexually Transmitted Disease (STD) and laboratory
testing will be performed, and HIV prevention service referrals will be initiated. Follow-up
will be on a monthly basis for the first three months, and then de-escalated to an
every-3-month interval.
The program stratifies participants into two cohorts on the basis of sexual risk behavior: a
low-moderate risk cohort (LM) and a high-risk cohort (H). Participants in the LM cohort will
be provided a customized prevention package (CPP) including access to PEP for emergency HIV
prevention in the event of unanticipated HIV exposure. Participants in the H cohort will be
provided a CPP including daily Truvada-based PrEP. All participants will be followed for 48
weeks. Participants in the LM cohort who, on longitudinal sexual risk behavior surveillance,
report increased levels of sexual risk-taking such that they meet enrollment criteria for the
H-cohort will be transitioned to the H-cohort.
At each follow-up visit, a careful safety assessment will be made, including signs/symptoms
and laboratory assessments. STD testing will be performed at 3 month intervals. An
escalating-intensity adherence intervention will be implemented based on real-time plasma
tenofovir levels. A computer-assisted self-interview (CASI) will be used to capture detailed
sexual risk, adherence, and substance use behavior.
which participants may present for screening for prevention services. At the sites,
eligibility criteria will be assessed, HIV, Sexually Transmitted Disease (STD) and laboratory
testing will be performed, and HIV prevention service referrals will be initiated. Follow-up
will be on a monthly basis for the first three months, and then de-escalated to an
every-3-month interval.
The program stratifies participants into two cohorts on the basis of sexual risk behavior: a
low-moderate risk cohort (LM) and a high-risk cohort (H). Participants in the LM cohort will
be provided a customized prevention package (CPP) including access to PEP for emergency HIV
prevention in the event of unanticipated HIV exposure. Participants in the H cohort will be
provided a CPP including daily Truvada-based PrEP. All participants will be followed for 48
weeks. Participants in the LM cohort who, on longitudinal sexual risk behavior surveillance,
report increased levels of sexual risk-taking such that they meet enrollment criteria for the
H-cohort will be transitioned to the H-cohort.
At each follow-up visit, a careful safety assessment will be made, including signs/symptoms
and laboratory assessments. STD testing will be performed at 3 month intervals. An
escalating-intensity adherence intervention will be implemented based on real-time plasma
tenofovir levels. A computer-assisted self-interview (CASI) will be used to capture detailed
sexual risk, adherence, and substance use behavior.
Inclusion Criteria:
- At least 18 years of age
- Able to understand and provide consent in English or Spanish
- Self identified MSM, MSM/W, or Transfemale
- At least one male sex partner for anal intercourse in the prior 12 months
- HIV negative by enzyme immunoassay (EIA) and viral load (VL)
- CrCl ≥ 60 ml/min (via Cockcroft-Gault formula)
- No signs or symptoms suggestive of primary HIV infection (PHI).
Exclusion Criteria:
- Participants <18 years of age
- Unable to understand and provide consent in English or Spanish
- Known or found on testing to be HIV positive
- Any condition, which in the opinion of the intake provider, will seriously compromise
the participant's ability to comply with the protocol, including adherence to PEP or
PrEP medication dosing
- Use of Antiretroviral therapy (ART) taken for any indication (i.e. PEP or PrEP) within
60 days of study entry
- Previous participation in an HIV vaccine trial. Participants that were documented to
have received only placebo are not excluded.
- Signs or symptoms suspicious for PHI.
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials